Objective: The objective of this study was to retrospectively evaluate the possibility of using the brachial veins despite their deep location, small caliber, and thin wall.
Results: For the 64 patients, cumulative primary patency rates (6 standard deviation [SD] ) at 1 year, 2 years, 3 years, and 4 years were 50% (67%), 42% (67%), 37% (68%), and 27% (611%), respectively. Primary assisted patency rates (6SD) at 1 year, 2 years, 3 years, and 4 years were 60% (66%), 51% (67%), 45% (67%), and 37% (69%), respectively. Secondary patency rates (6SD) at 1 year, 2 years, 3 years, and 4 years were 60% (66%), 53% (67%), 53% (67%), and 45% (68%), respectively. Early complications included thrombosis, nonmaturation, and upper arm edema. At the second stage (n ¼ 50), four patients presented with unexplained major fibrosis extending cephalad from the first surgical site and preventing any dissection of the vein. Four patients had more usual complications (one nonmaturation, two occlusions of the brachial vein at the previous arteriovenous graft-vein anastomosis), and two were lost to follow-up. Vein transposition in a subcutaneous tunnel was technically unfeasible in eight patients. Of the 64 patients, 40 (62%) had a functional BrVT that was cannulated for effective dialysis after a median interval of 72 days (15-420 days) from the first stage. Mean cumulative secondary patency rates (from first cannulation) at 1 year, 2 years, and 3 years were 91% 6 5%, 72% 6 8%, and 62% 6 10%, respectively. Overall, 13 patients were lost to follow-up. Secondary complications were low flow and central vein occlusion. Long-term complications were related to stenosis and thrombosis, aneurysms, and puncture site necrosis. Median follow-up from the first stage was 1.62 years (0.02-11.3 years). Chronic kidney disease is a major public health problem worldwide. Since 2006, National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines (currently being revised) have tried to present a structured approach to the choice of type and location of long-term angioaccess for hemodialysis and for treatment of sickle cell disease to minimize complications and to optimize access survival. An autologous arteriovenous fistula (AVF) is the preferred long-term access because of its lower rate of complications and longer survival of both the access and the patient.
1-3 Prosthetic grafts should be considered only in the absence of a suitable vein. One way of extending the availability of an autologous vein is to consider one of the two brachial veins as a plausible choice in the absence of other possibilities in the upper extremities. [4] [5] [6] [7] [8] We report our experience using this vein for brachial vein transposition (BrVT) in terms of maturation, patency, and complications.
METHODS
New BrVT access was created for hemodialysis in 54 patients, blood exchange or transfusion in 9 patients, and long-term parenteral nutrition in 1 patient. Candidates referred for vascular access were considered for BrVT when no other upper extremity autologous vascular access was possible. Characteristics of the patients are listed in the Table. This retrospective study includes 64 patients who underwent BrVT as an ultimate autologous arteriovenous angioaccess from March 1991 to May 2014. Because of this long time and care necessities, Institutional Review Board approval was waived and informed consent of the patients for publication was not obtained. Initially, BrVT was rarely performed. Later, it became more frequent. All BrVTs were created by two different surgeons using the same indications and techniques since 2008.
Preoperative evaluation was based on history of previous angioaccesses, clinical examination, and vein mapping by venography or color duplex ultrasound in every patient to confirm the impossibility of creating other autologous AVFs and to evaluate brachial vein patency and approximate caliber. Color duplex ultrasound has recently become the de facto standard. However, we learned from our early prevenography experience that venography is systematically required in patients with a history of central vein catheter (CVC).
Surgery was achieved in two stages in all patients but one. Ultrasound-guided local-regional anesthesia and no-touch surgical technique without vein infusion or distention were used in each case. 9 For the first stage, preventive hemostasis was achieved by an inflatable or narrow elastic tourniquet for better vision and prevention of possible arterial spasm related to dissection. 10, 11 The skin incision was made over the medial part of the elbow crease, and both brachial veins were evaluated after incision of the aponeurosis. The medial brachial vein, which has a more direct path to join the axillary vein, was preferred to the lateral brachial vein for creation of a side-to-end anastomosis with the brachial artery whenever possible. The anastomosis was performed using an operating microscope, microsurgical instruments, and 9-0 sutures. 12 Color duplex ultrasound and clinical examinations were systematically performed at 1 month after each stage to assess vein wall thickening, vein diameter >6 mm, and flow >600 mL/min. There were no cases of balloonassisted maturation. In two patients, no maturation was seen at the second stage of surgery, which was abandoned. Second-stage surgery was performed after a median interval of 2.3 months (0.8-14 months) after the first-stage surgery using a long skin incision for dissection of the vein with ligation of collaterals (Fig 1) . The vein was divided at the elbow level, transposed anteriorly in a superficial tunnel, and reanastomosed higher up on the brachial artery.
Success (maturation) was defined as creation of an access able to deliver a flow rate of 350 to 400 mL/min without access recirculation to maintain a treatment time of <4 hours. Patency was checked monthly (Transonic, Ithaca, NY) in most hemodialysis centers and every 6 months by color duplex ultrasound examination. 
RESULTS
Sixty-four patients were considered for two-stage BrVT in the upper arm apart from one who had a one-stage procedure after a previous long-term ulnar-basilic wrist fistula. A prior upper arm arteriovenous graft (AVG) or BrVT may complicate superficialization of the brachial vein without evident deleterious effect on maturation or use of the access. There were 54 patients who were already on dialysis (18 AVFs, 36 CVCs); their current angioaccess was used during BrVT creation and maturation. Four CVCs were ipsilateral to BrVT because of complete occlusion of the contralateral central vein. Sickle cell disease red blood cell exchanges were performed through an implantable port (n ¼ 6) or temporary femoral catheter (n ¼ 3).
Cumulative patency. Primary patency rates (6 standard deviation [SD]) at 1 year, 2 years, 3 years, and 4 years were 50% (67%), 42% (67%), 37% (68%), and 27% (611%), respectively (Fig 2) . Primary assisted patency rates (6 SD) at 1 year, 2 years, 3 years, and 4 years were 60% (66%), 51% (67%), 45% (67%), and 37% (69%), respectively. Secondary patency rates (6 SD) at 1 year, 2 years, 3 years, and 4 years were 60% (66%), 53% (67%), 53% (67%), and 45% (68%), respectively.
Perioperative complications. First-stage BrVT was performed in 64 patients (Fig 3) . Four patients were immediately lost to follow-up. Ten patients had complications that precluded any secondary operation or second-stage superficialization. Three of them presented with major upper extremity edema, which unmasked a high-grade central vein stenosis associated with an indwelling ipsilateral CVC. This occurred before our routine use of preoperative venography. The fistulas were closed by percutaneous insertion of a vascular plug in the perianastomotic segment of the vein. 16 There were four nonmaturations before the second stage with flow <300 mL/min compared with a median flow of 1250 mL/min (660-2000 mL/min) in the 40 patients who had a patent fistula after superficialization. Three patients had outflow stenosis. In one patient, the stenosis was related to a fistula erroneously created using the medial brachial vein while this vein was interrupted proximally after a previous upper arm AVG (Fig 4) . In the other two patients, the arterialized lateral brachial vein was compressed on crossing the brachial artery posteriorly to join the medial vein. All three patients experienced thrombosis before the second stage despite adequate 1-month flows of 480, 800, and 1000 mL/min, respectively, and their accesses were abandoned. There were 50 patients who were candidates for second-stage surgery (superficialization). Three patients were lost to postoperative follow-up. Vein transposition in an anterior tunnel could not be performed in seven patients; dissection of the brachial vein was impossible in four of these patients, including one in whom it was not feasible to dissect the midportion of the fibrotic vein that crossed the brachial artery posteriorly. In two others, major fibrosis extending cephalad from the anastomosis to the mid-third upper arm prevented any dissection. In the final patient, resection of a prior polytetrafluoroethylene graft for tunnelization of the brachial vein was impossible, and a simple elevation of the brachial vein was performed. During surgery, two severe mid-brachial vein stenoses were discovered. In one patient, we were surprised by the small caliber of the veins (<1.5 mm), and superficialization was canceled.
ARTICLE HIGHLIGHTS
Success. Of 64 patients, 40 (62%) had a functional BrVT that was cannulated for effective dialysis after a median interval of 72 days (15-420 days) from the first stage.
Secondary complications. One postoperative superficial infection was successfully treated with antibiotics. One hemodialysis access-induced distal ischemia occurred. Angiography revealed that the surgeon had erroneously superficialized the nonarterialized vein, effectively creating two fistulas. Ischemia was easily cured by vascular plug occlusion of the first anastomosis.
Late complications. One brachial vein was too short, and the axillary vein was successfully superficialized to add additional length. Localized aneurysmal degeneration at puncture sites occurred at a median interval of 2.7 years (range, 2.4-3.7 years) from first-stage surgery. Five aneurysms were surgically repaired. One high-flow fistula was reduced by transposition of the radial artery. 17 Six patients required percutaneous transluminal angioplasty (PTA) to maintain patency; four patients had one PTA and two patients had three.
Cumulative secondary functional patency. For the 40 cannulated patients, cumulative secondary functional patency rates (from first cannulation; 6 SD) at 1 year, 2 years, and 3 years were 91% (65%), 72% (68%), and 62% (610%), respectively. Finally, of the 64 patients who were candidates for BrVT, 50 underwent second-stage superficialization, and 40 were successfully cannulated. Anatomy. Deep brachial veins (venae comitantes) are traditionally described as deep, fragile, small-caliber, and paired satellite veins of the brachial artery from the elbow to the axilla, interconnected by many collaterals. The brachial vein, which is medial to the brachial artery, is joined by the basilic vein in the higher part of the upper arm. Near the axilla, the lateral brachial vein crosses the brachial artery (anteriorly or posteriorly) to join the medial brachial vein to form the large axillary vein.
Anaya-Ayala et al 21 have identified three types of brachial and basilic vein anatomy in the upper arm after preoperative color duplex ultrasound mapping in 290 patients. Paired brachial veins were present in 83% of the mapped upper arms (Fig 6) . The medial brachial vein has the most direct path to the axillary vein. Patients with type 2 or type 3 (short basilic vein, 34% of population) are occasionally but erroneously included in cohorts of brachial vein superficialization patients. In fact, as pointed out by Schanzer, these patients received a transposition of an initially large and resistant basilic vein with some proximal deep brachial vein extension. 8 Another variant of brachial anatomy is an early bifurcation of the brachial artery originating anywhere from above the elbow to the axilla. In these patients, the most superficial vessels in the elbow under the bicipital fascia are not brachial vessels but small-caliber radial artery and veins; the larger ulnar-interosseous artery and veins are more deeply situated.
22 Surprisingly, this frequent variation (15%-25% of the population) is rarely mentioned in angioaccess articles or even those related to BrVT. In such a situation, in performing first-stage BrVT, it might be preferable to create the anastomosis with the larger ulnar-interosseous artery and veins that are beneath the thin radial vessels, knowing there is a risk of inducing high flow. If, during the secondstage surgery, small-caliber veins (<1.5 mm) are encountered compared with duplex flow measurements >300 mL/min in the brachial artery, a high brachial artery bifurcation should be suspected with deeper large ulnar-interosseous vessels. Early in our experience, as mentioned before, after the second-stage elbow incision in one patient, we were surprised by the small caliber of the veins (<1.5 mm). Retrospectively, we suspect that a deeper initial ulnar-interosseous anastomosis had been created at the first stage with an unidentified high brachial artery bifurcation.
Microsurgery. Both of our surgeons used a surgical microscope. 23, 24 In our experience, after training on rats in the laboratory, microsurgery for AVF creation resulted in a dramatic benefit in wrist AVF creation, maturation, and early and long-term patency rates. An operating microscope is mandatory for pediatric access, very helpful for wrist fistulas in adults, and most recommended for first-stage BrVT. Microscopes are available in many institutions and are routinely used in many specialties, including access surgery.
Choice of the vein. Accurate evaluation of both brachial veins with color duplex ultrasound and venography may be difficult because of their small caliber (to our knowledge, no publications with measurements), deep location under the aponeurosis, and presence of many collaterals. The use of a tourniquet is of little help in studying the diameter, patency, continuity, and elasticity of each vein. Moreover, at surgery, it may be difficult to discriminate between the lateral and medial brachial veins in case of slight rotation of the upper arm. Finally, it may be challenging to identify an early bifurcation of the brachial artery before the vessels dilate after the first-stage anastomosis. At first-stage surgery, when the medial and lateral brachial veins have different calibers, most surgeons prefer to choose the larger one. In fact, the best choice would be the medial brachial vein, which has the most direct path to the axillary vein. Preoperative duplex ultrasound imaging is most important to avoid using a lateral brachial vein encircling or crossing the brachial artery early and posteriorly to join the medial vein. Finally, it may be difficult to differentiate between the two veins. To the surgeon's eye, they frequently appear more anterior and posterior than lateral and medial.
In contrast to several other authors, we had no minimal cutoff vein diameter. Small vein diameters were not an issue because we used an operating microscope and 9-0 sutures for the first-stage anastomosis to obtain the best possible immediate patency. However, 9 of the 24 early failures included 3 thromboses and 4 nonmaturations, which may have been related in part to a small anastomosis.
Fibrosis. Major perivenous fibrosis observed in four patients was possibly related to a previous upper arm AVG in one patient, to blind vein cannulations for frequent blood transfusions in another patient, and to intravenous drug addiction in a third. No possible explanation was found for the last patient. Routinely, such fibrosis is absent at the time of first-stage surgery. It is possible that postoperative bleeding through the anastomosis or through the thin wall of the vein may be the cause. In each of these patients, extensive fibrosis precluded any dissection and transposition of the vein; even AVF ligation could not be done. Consequently, the fistulas were occluded with a percutaneous vascular plug.
Venous hypertension. We observed major arm edema after the first stage in three patients with a CVC ipsilateral to the BrVT. Because of the fragility of the recently arterialized vein with risk of rupture at PTA, massive edema, and the uncertainty of the fistula's future, it was decided to close the AVF. In these conditions, open surgery with ligation of the arteriovenous anastomosis would have been technically demanding. Percutaneous insertion of multiple coils in one patient and plug insertion in the juxta-anastomotic part of the vein in two patients were considered less invasive and were favored in these cases.
Significant forearm swelling was not observed after BrVT. No forearm distal compartment syndrome has occurred to date after BrVT, although two cases have been reported in the lower leg after femoral vein superficialization in similar conditions due to venous hypertension. 23, 25 One-stage vs two-stage procedures. Brachial vein superficialization was performed in one stage by Koontz and Helling, who reported two cases in 1983. 4 Our first BrVT (1991) was undertaken in one stage after a failed long-term ulnar-basilic wrist AVF. Most surgeons rapidly moved to the two-stage procedure unless the vein diameter was >6 mm due to a previous forearm AVF. 7, 8, 18, 19 Tunnelization vs elevation. All our patients except one benefited from superficialization through an anterior subcutaneous tunnel. This procedure is used routinely for BrVT and respects the medial antebrachial cutaneous nerve. Some authors prefer elevation/shelf superficialization of the vein under the anterior border of the incision. This technique is quicker and simpler and may be useful when the dissected brachial vein is too short for tunnelization or when a previous upper arm angioaccess is difficult to dissect free. 20 From our personal experience, the elevated vein may move down under the scar, making cannulation and subsequent healing difficult, especially in the case of hypertrophic scarring.
Functional patencydBrVT vs upper arm AVG. Primary and secondary patency rates after BrVT creation were calculated using Kaplan-Meier and life-table methods (Fig 2) . Reporting also functional secondary patency starting from the first effective dialysis (or use), with exclusion of primary failures, is now considered justified by several authors. 3, 15, 18 In a cohort of patients like ours with no superficial vein, Pham et al reported a comparison of 29 BrVTs with 32 AVGs in the forearm or upper arm. 26 Our BrVT experience shows superior results with 91% (65%) 1-year secondary functional patency compared with 52% for BrVT and 47% for AVG in their recent publication.
Study limitations. This is a retrospective nonrandomized study covering an extended period. Many early failures were abandoned because of the unknown outcomes of BrVT. The reasons for the four cases of major fibrosis at the second-stage surgery remain unclear. More experience is necessary. We believe that our admittedly high nonmaturation rate could be attributed to many causes: learning curve, absence of selection, small-caliber vein, much smaller vein in case of early bifurcation of the brachial artery, high rates of catheter-related central vein stenosis, high number of patients lost to follow-up, occasional extensive perivenous fibrosis after the first stage, thin vein wall with poor resistance to tunnelization, possible porosity of the vein due to high-pressure inflow and outflow (small vein, central vein stenosis), difficulty in identifying the arterialized vein at the second stage, and absence of color duplex ultrasound and venography standards.
By adding our long-term experience with many patients and complications to the BrVT literature, we wish to sound a word of caution in patients with a previous upper arm AVG, high bifurcation of the brachial artery, or significant central vein stenosis and an unexplained complication such as perivenous fibrosis or the risk associated with use of the lateral vein when it crosses the brachial artery posteriorly. We underscore the major importance of duplex ultrasound imaging, microsurgery, and percutaneous plug insertion for closing the AVF in selected patients. Greater standardization of duplex ultrasound imaging criteria and indications for BrVT creation are necessary to increase maturation rates and to reduce delayed maturation. We consider our current secondary patency rates satisfactory.
Alternative access. Alternative angioaccess to BrVT exists. Primary AVG to a patent proximal segment of the basilic vein remains an option that may decrease catheter-days in selected patients. In our experience, upper arm AVG anastomosis to one of the two small brachial veins is at risk of early stenosis. Thigh AVGs may be prone to infection. Femoral vein superficialization is associated with long-term patency but carries a risk of high flow and distal ischemia. 24, 25 
CONCLUSIONS
Transposition of small and fragile brachial veins presents many pitfalls for the surgeon. Our early failure rates were high (40%). After successful staged transposition, our fistulas had long survival with few reinterventions compared with polytetrafluoroethylene grafts. Once the cephalic and basilic veins are no longer available, BrVT is the last possible autologous arteriovenous access in the upper extremity. Preoperative clinical and imaging criteria need to be defined for optimal selection of patients. 
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